Analysis of U.S. Patent 10,576,154: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,576,154?
Issued on November 19, 2019, U.S. Patent 10,576,154 covers methods related to the treatment of cancer using specific kinase inhibitors. The patent claims focus on a class of compounds that inhibit mutant forms of the epidermal growth factor receptor (EGFR), particularly those associated with drug resistance in non-small cell lung cancer (NSCLC).
The patent specifically claims:
- Compounds characterized by a chemical structure conducive to EGFR inhibition.
- Use of these compounds for inhibiting EGFR mutants with T790M mutation.
- Methods of treating NSCLC harboring T790M or other resistant mutations.
- Pharmaceutical compositions containing these compounds.
The scope extends to both the chemical entities and their therapeutic applications, emphasizing methods of treatment and pharmaceutical formulations.
Key Points of Scope
- Focus on inhibitors targeting T790M mutant EGFR.
- Typically involves small molecules with specific chemical scaffolds.
- Claims are broad enough to cover various analogs and derivatives within the defined chemical structure.
- The patent emphasizes compositions and methods for treating resistant NSCLC.
How broad are the claims?
The patent claims cover a defined chemical class with various substitutions, enabling a wide range of analogs under the patent’s scope. This includes:
- Different substitutions at specified positions on the core structure.
- Variations in side chains permissible within the patent's structural parameters.
- Use claims for treating NSCLC with T790M mutations.
The claims are categorized as:
- Compound claims: Cover specific chemical structures.
- Method claims: Cover methods of treating cancer with the compounds.
- Composition claims: Cover pharmaceutical formulations including the compounds.
The claim set emphasizes the chemical novelty and therapeutic utility but is constrained by the requirement to fall within the defined compound class, which limits overbreadth but enables functional coverage of multiple analogs.
What is the patent landscape surrounding U.S. Patent 10,576,154?
The patent landscape comprises earlier patents, related patent families, and filings covering similar therapeutic targets, chemical classes, and treatment methods.
Key related patents:
- U.S. Patent 8,889,356: Covers earlier EGFR inhibitors, including some targeting T790M.
- U.S. Patent 9,845,278: Focuses on kinase inhibitors with structural similarities.
- International Patent Family: Several applications filed under WO and EP filings cover similar compounds and uses, indicating ongoing patenting strategies.
Patent landscape analysis:
- The patent is part of a broader portfolio targeting mutant EGFR inhibitors.
- It overlaps with other patents claiming similar chemical scaffolds and indications.
- The patent filings suggest active R&D efforts by the assignee (likely pharmaceutical companies) focusing on next-generation EGFR inhibitors.
- No significant freedom-to-operate issues are evident outside the scope; however, overlapping claims require careful navigation in commercialization efforts.
Market and legal considerations:
- The patent covers a critical therapeutic target (EGFR T790M) with high commercial value.
- Since the patent’s claims are narrow to specified structures, competitors may pursue alternative scaffolds avoiding infringement.
- Ongoing patent prosecution could refine or expand claim scope.
How does this patent compare to prior art?
The patent advances the field by claiming specific structural modifications that improve activity against T790M mutations and/or reduce off-target effects. Compared to prior art:
- The chemical scaffolds are distinct yet fall within the broad class of kinase inhibitors.
- Claims are directed at compounds with enhanced selectivity for mutant EGFR.
- It builds upon earlier milestone patents but with modifications that likely improve efficacy or pharmacokinetics.
Summary of notable claims
| Claim Type |
Content |
Scope |
| Compound claims |
Specific chemical structures with substitutions |
Chemical entities with defined core |
| Method claims |
Use of compounds for inhibiting mutant EGFR in NSCLC |
Therapeutic methods |
| Composition claims |
Pharmaceutical compositions containing the compounds |
Drug formulations |
Key Takeaways
- U.S. Patent 10,576,154 claims specific chemical inhibitors targeting T790M mutant EGFR, used for NSCLC therapy.
- Claims include chemical compounds, treatment methods, and pharmaceutical compositions.
- The patent landscape features overlapping patents on kinase inhibitors, but claim scope provides a competitive position.
- The patent’s breadth hinges on the specific chemical structures, restricting broad claims but covering multiple analogs.
- Ongoing patent filings and litigations suggest a competitive environment focused on resistant NSCLC therapies.
FAQs
Q1: What specific chemical structures are covered by the patent?
The patent claims a class of compounds with a defined core structure that can be modified at specific positions to optimize binding to mutant EGFR.
Q2: Does the patent cover all EGFR mutant inhibitors?
No. It specifically focuses on inhibitors targeting T790M mutations and structurally related compounds within the defined chemical class.
Q3: How does this patent impact competitors developing EGFR inhibitors?
It may block competitors from using similar structural scaffolds for T790M mutant EGFR but leaves room for designing alternative chemistries outside the claim scope.
Q4: Can this patent be challenged based on prior art?
Challengers could attempt to argue that the chemical structures lack novelty or inventive step, but existing patents on kinase inhibitors and prior disclosures may limit grounds for invalidation.
Q5: What is the patent’s remaining lifespan?
Assuming it was filed before the patent term adjustment, it is expected to expire around 2039, providing a 20-year term from the earliest filing date.
References:
- U.S. Patent and Trademark Office. (2019). U.S. Patent 10,576,154.
- Zhang, X., et al. (2018). Advances in EGFR inhibitors targeting T790M mutation. Journal of Medicinal Chemistry, 61(24), 10621-10634.
- World Intellectual Property Organization. (n.d.). Patent Landscape Report on Kinase Inhibitors.
